Tiziana Life Sciences (TLSA) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free TLSA Stock Alerts $0.78 -0.06 (-7.14%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsproactiveinvestors.com - April 25 at 10:59 AMTiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumabglobenewswire.com - April 25 at 10:00 AMTiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Programproactiveinvestors.com - April 23 at 8:43 AMTiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Programglobenewswire.com - April 23 at 7:00 AMTiziana Life Sciences reports additional positive results from Multiple Sclerosis programproactiveinvestors.com - April 22 at 8:49 AMTiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Programglobenewswire.com - April 22 at 7:00 AMTiziana Life Sciences' foralumab study highlighted in Neurology Todayproactiveinvestors.com - April 19 at 9:09 AMTiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®globenewswire.com - April 19 at 7:00 AMTiziana Life Sciences says foralumab shows promise in stabilizing certain types of MSproactiveinvestors.com - April 18 at 9:30 AMTiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurologyglobenewswire.com - April 18 at 7:00 AMTiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conferenceproactiveinvestors.com - April 11 at 9:11 AMTiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurologyglobenewswire.com - April 11 at 7:00 AMTLSA Tiziana Life Sciences Ltdseekingalpha.com - March 20 at 4:45 PMTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Diseasefinance.yahoo.com - March 5 at 10:39 AMTiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's diseaseproactiveinvestors.com - March 5 at 8:27 AMTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Diseaseglobenewswire.com - March 5 at 7:00 AMTiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024finance.yahoo.com - January 5 at 1:32 PMTiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammationfinance.yahoo.com - January 5 at 8:32 AMTiziana Life Sciences starts Phase 2a trial and promises results in 2024proactiveinvestors.com - December 22 at 9:47 AMTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosisfinance.yahoo.com - December 19 at 9:00 AMTiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinarfinance.yahoo.com - December 4 at 9:52 AMTiziana Life Sciences advances multiple sclerosis research...Tiziana Life Sciences advances multiple sclerosis research program...proactiveinvestors.com - November 30 at 8:37 AMTiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosisfinance.yahoo.com - November 30 at 8:37 AMTiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023finance.yahoo.com - November 1 at 8:42 AMTLSA: Six Month SPMS Resultsfinance.yahoo.com - October 20 at 2:00 PMTiziana Life Sciences: FDA signs off on home-based protocol for MS treatmentproactiveinvestors.com - October 18 at 8:51 AMTiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatmentfinance.yahoo.com - October 18 at 8:51 AMTiziana Life Sciences reveals "exciting" clinical data from latest MS trialproactiveinvestors.com - October 16 at 10:16 AMTiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)finance.yahoo.com - October 13 at 7:52 AMTiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congressfinance.yahoo.com - October 11 at 7:58 AMTiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMSproactiveinvestors.com - September 26 at 8:32 AMPoised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidatebenzinga.com - September 22 at 2:49 PMTiziana $TLSA: Analyst Anticipates Promising Developments in Foralumab Trials for SPMS & Alzheimer'smsn.com - September 22 at 2:49 PMTiziana Life Sciences' Alzheimer's treatment validated in new studyfinance.yahoo.com - September 12 at 5:55 PMB.Riley Financial Sticks to Its Buy Rating for Tiziana Life Sciences (TLSA)markets.businessinsider.com - September 8 at 9:06 AMTiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 8 at 9:06 AMTiziana Life Sciences highlights publication of promising Alzheimer’s study resultsproactiveinvestors.com - September 6 at 6:11 PMTiziana Life highlights promising Alzheimer’s study resultsproactiveinvestors.com - September 6 at 6:11 PMStudy Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearancefinance.yahoo.com - September 6 at 8:31 AMTLSA: IND Cleared by FDA and Alzheimer’s Deep Divefinance.yahoo.com - August 28 at 4:46 PMTiziana Life's investigational therapeutic foralumab to get spotlight at neuroimmunology eventproactiveinvestors.com - August 23 at 6:06 PMTiziana’s foralumab spotlighted at neuroimmunology event; chief development officer appointedproactiveinvestors.com - August 23 at 6:06 PMTiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officerfinance.yahoo.com - August 23 at 6:06 PMTiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatmentfinance.yahoo.com - August 17 at 4:47 PMTiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Diseasefinance.yahoo.com - August 17 at 9:18 AMTiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervisionbenzinga.com - August 16 at 6:17 PMTiziana Life Sciences Gets FDA Clearance for Possible Alzheimer's Treatmentmarketwatch.com - August 15 at 4:49 PMTiziana climbs as FDA clears trial for intranasal Alzheimer’s drugseekingalpha.com - August 15 at 4:49 PMWhy Tiziana Life Sciences Stock (TLSA) Is Climbingbenzinga.com - August 15 at 4:49 PMTiziana Life Sciences (NASDAQ:TLSA) Jumps 45% as FDA Greenlights Alzheimer Trialmsn.com - August 15 at 4:49 PM Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. TLSA Media Mentions By Week TLSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSA News Sentiment▼0.500.32▲Average Medical News Sentiment TLSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSA Articles This Week▼71▲TLSA Articles Average Week Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CNTX News Today GRFS News Today LVTX News Today MYNZ News Today NLSP News Today PHVS News Today ACONW News Today DRTSW News Today AONC News Today ARTLW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
